Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558]
Discontinued
Reference number: GID-TA10875
Following on from information provided to NICE by the company in May 2021, the appraisal of Durvalumab with tremelimumab for treating recurrent or metastatic squamous-cell head and neck cancer [ID1558] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.